Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus CL1285
- Development stage
- Unknown
- Lead developer
- Bio-K+
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus acidophilus CL1285 is a proprietary probiotic bacterial strain originally developed by Bio-K+ International (now part of Kerry Group). It is the primary constituent of the Bio-K+ probiotic line, often formulated alongside Lacticaseibacillus casei LBC80R and Lacticaseibacillus rhamnosus CLR2. The strain is clinically recognized for its efficacy in the primary prevention of Clostridioides difficile infection (CDI) and antibiotic-associated diarrhea (AAD) in hospitalized patients. Its therapeutic effects are mediated through the modulation of the gut microbiota, competitive inhibition of pathogens, and the production of antimicrobial metabolites. Furthermore, L. acidophilus CL1285 has demonstrated the ability to neutralize C. difficile toxins A and B and possesses enzymatic activities, such as bile salt hydrolase and feruloyl esterase, which suggest potential benefits in managing dyslipidemia and hypercholesterolemia. It is also investigated for its role in improving symptoms of irritable bowel syndrome (IBS) and chronic hand dermatitis.
- Brand names
- Bio-K+
- Other names
- Lactobacillus acidophilus CL1285L. acidophilus CL1285
02
Targets
TcdA (Clostridioides difficile toxin A)BSH (Bile salt hydrolase)TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on lactobacillus acidophilus CL1285.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus CL1285.